Date | Price Target | Rating | Analyst |
---|---|---|---|
6/17/2024 | $88.00 | Buy | Truist |
5/24/2024 | $86.00 → $73.00 | Buy | H.C. Wainwright |
5/23/2024 | $60.00 | Buy | Deutsche Bank |
4/17/2024 | $65.00 | Sector Perform → Sector Outperform | Scotiabank |
4/3/2024 | $82.00 | Overweight | Cantor Fitzgerald |
3/13/2024 | $86.00 | Outperform | Raymond James |
12/19/2023 | Sector Perform | Scotiabank | |
11/6/2023 | $90.09 | Buy | Goldman |
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $186 millionMHRA and Health Canada approved CARVYKTI® in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myelomaCARVYKTI® demonstrates positive overall survival results in second interim analysis of CARTITUDE-4 studyCash and cash equivalents, deposits and short-term investments of $1.3 billion, as of June 30, 2024, which Legend Biotech believes will provide financial runway into 2026, when Legend Biotech anticipates achieving an operating profit SOMERSET, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a globa
SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced preliminary, unaudited financial results for the six-months ended June 30, 2024. For the six-months ended June 30, 2024, Legend Biotech expects to record an adjusted net loss for the period of approximately $94.7 million to $109.7 million. See "Use of Non-IFRS Financial Measures" below for a reconciliation of net loss to adjusted net loss for the first six months of the year. This preliminary estimated data should not be considered as a substitute for the full unaudited financial results for the six-months ended June 30, 2024, w
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentation section approximately tw
These ten large-cap stocks were the best performers in the last week. Are they in your portfolio? Warner Bros. Discovery, Inc. (NASDAQ:WBD) stock escalated 18.28% after a report that the company had discussed plans to split its digital streaming and studio businesses from its legacy television networks. MicroStrategy Inc.’s (NASDAQ:MSTR) stock gained 16.74% last week amid a rise in Bitcoin’s price. D.R. Horton, Inc. (NYSE:DHI) shares surged 12.91% after the company reported better-than-expected Q3 financial results and revised FY24 guidance. The company also authorized a new $4 billion share repurchase. Few analysts raised the price forecasts on the stock. Coinbase Global Inc.’s
Scotiabank analyst George Farmer maintains Legend Biotech (NASDAQ:LEGN) with a Sector Outperform and raises the price target from $65 to $70.
U.S. stocks were higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Cintas Corporation (NASDAQ:CTAS) rose during Thursday's session after the company reported better-than-expected quarterly EPS and revenues. Cintas reported fourth-quarter earnings per share of $3.99, beating the street view of $3.80. The company registered quarterly revenues of $2.471 billion, beating the street view of $2.468 billion, according to data from Benzinga Pro. Cintas shares gained 5.3% to $758.25 on Thursday. Here are some other big stocks recording gains in today’s session. Chuy’s Holdings, Inc. (NASDAQ:CHUY) shares gained 47.6% to $37.29 after the company and Darde
6-K - Legend Biotech Corp (0001801198) (Filer)
6-K - Legend Biotech Corp (0001801198) (Filer)
6-K - Legend Biotech Corp (0001801198) (Filer)
SC 13G/A - Legend Biotech Corp (0001801198) (Subject)
SC 13G/A - Legend Biotech Corp (0001801198) (Subject)
SC 13G/A - Legend Biotech Corp (0001801198) (Subject)
Truist initiated coverage of Legend Biotech with a rating of Buy and set a new price target of $88.00
H.C. Wainwright reiterated coverage of Legend Biotech with a rating of Buy and set a new price target of $73.00 from $86.00 previously
Deutsche Bank initiated coverage of Legend Biotech with a rating of Buy and set a new price target of $60.00
SOMERSET, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Peter Salovey, Ph.D., President Emeritus of Yale University, to its Board of Directors. Dr. Salovey will serve as an independent director, effective August 9. "We are pleased to welcome Dr. Salovey to the Legend Board," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "Dr. Salovey's deep experience and wealth of knowledge in medical research and public health will be invaluable to Legend and offer a new and diverse perspective. We look forward to his insights and contributions to the strategic dec
Legend Biotech Corporation ("Legend Biotech" or the "Company") (NASDAQ:LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of Mythili Koneru, M.D., Ph.D. as the Company's Chief Medical Officer. In this role, Dr. Koneru will be responsible for overseeing the Company's clinical development and medical affairs programs. Dr. Koneru joins Legend Biotech from Marker Therapeutics, where she served as Chief Medical Officer, leading the development of the company's cell therapies and peptide vaccines in its immuno-oncology portfolio. Prior to her time at Marker Therapeutics, Dr. Kone
Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the promotion of Lori Macomber, CPA, to Chief Financial Officer (CFO), effective immediately. Ms. Macomber assumes the role from Dr. Ying Huang, who has been both CFO and Chief Executive Officer (CEO) since September 2020. Dr. Huang will continue to serve as CEO of Legend Biotech. "Lori is a highly valued leader and strategic thought partner that has been instrumental in building the company's finance organization," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "Lori p
PISCATAWAY, N.J., Aug. 27, 2024 /PRNewswire/ -- Legend Biotech (NASDAQ:LEGN), a subsidiary of GenScript Biotech Corporation (hereinafter referred to as "GenScript"), a global leader in life sciences research and manufacturing services, today announced that they have received approval from the China National Medical Products Administration (NMPA) for its cell therapy product, ciltacabtagene autoleucel (cilta-cel). This groundbreaking treatment is approved for use in adult patients with relapsed or refractory multiple myeloma (MM) who have previously undergone at least three prior lines of therapy, including at least one proteasome inhibitor and one immunomodulatory agent. The approval of cilt
SOMERSET, N.J., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on Wednesday, September 4, 2024, at 2:35 p.m. ET. The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of Legend's website. The webcast replay will be available approximately 48 hours after the webcast. ABOUT LEGEND BIOTECH Legend Biotech is a global biotechnology company dedicated t
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $186 millionMHRA and Health Canada approved CARVYKTI® in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myelomaCARVYKTI® demonstrates positive overall survival results in second interim analysis of CARTITUDE-4 studyCash and cash equivalents, deposits and short-term investments of $1.3 billion, as of June 30, 2024, which Legend Biotech believes will provide financial runway into 2026, when Legend Biotech anticipates achieving an operating profit SOMERSET, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a globa